Newsfeeds - Spark Newswire

2 minute read

Agenus Reports Balstilimab Plus Zalifrelimab Data Published In ‘Journal Of Clinical Oncology’: ‘Objective response rate (ORR) of 32.8%’

Today, 2:15 PM

Objective response rate (ORR) of 32.8% in PD-L1-positive patients and 25.6% in all patients regardless of PD-L1 status Both ORRs and durability of responses are higher than what has been demonstrated with approved

AGEN

20 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For December 16, 2021

By Benzinga Insights

Today, 2:15 PM

ABNB

1 minute read

HC Wainwright & Co. Initiates Coverage On Agenus with Buy Rating, Announces Price Target of $12

By Benzinga Newsdesk

Today, 2:15 PM

HC Wainwright & Co. analyst Michael King initiates coverage on Agenus (NASDAQ:AGEN) with a Buy rating and announces Price Target of $12.

AGEN

1 minute read

Agenus Posts Early Data For CTLA-4 Drug Candidate Across Tumor Types

By Vandana Singh

Today, 2:15 PM

In a Phase I study across nine tumor types, Agenus Inc’s (NASDAQ:AGEN) CTLA-4 drug AGN1181 posted one complete response and three…

AGEN

6 minute read

The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data

By Shanthi Rexaline

Today, 2:15 PM

Here's a roundup of top developments in the biotech space over the last 24 hours:

ACHV

1 minute read

Agenus Q3 EPS $0.72 Beats $0.46 Estimate, Sales $252.95M Beat $183.11M Estimate

By Benzinga Newsdesk

Today, 2:15 PM

Agenus (NASDAQ:AGEN) reported quarterly earnings of $0.72 per share which beat the analyst consensus estimate of $0.46 by 56.52 percent. This is a 357.14 percent increase over losses of $(0.28) per share from the same

AGEN

21 minute read

Earnings Scheduled For November 9, 2021

By Benzinga Insights

Today, 2:15 PM

Companies Reporting Before The Bell • Imara (NASDAQ:IMRA) is projected to report earnings for its third quarter. • KT (NYSE:KT) is projected to report earnings for its third quarter.

AAIC